{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:06:18Z","timestamp":1789023978462,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003142","name":"Fonds NutsOhra","doi-asserted-by":"publisher","award":["project 1202\u201331"],"award-info":[{"award-number":["project 1202\u201331"]}],"id":[{"id":"10.13039\/501100003142","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The ULTRA trial demonstrated no improvement in clinical outcome at 6\u00a0months in patients with subarachnoid hemorrhage (SAH) when treated with ultra-early and short-term tranexamic acid (TXA). In this post hoc analysis, we evaluated the effect of TXA in females and males on clinical outcome after aneurysmal SAH (aSAH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The ULTRA trial was a prospective, randomized, controlled, open-label trial, conducted between 2013 and 2020. Patients with spontaneous SAH were assigned to ultra-early, short-term TXA in addition to usual care, or usual care only. In this study, we only included ULTRA participants with radiologically proven aSAH. We analyzed the potential effect of sex on the association between treatment group and clinical outcome by assessing effect modification, and evaluated the effect of TXA separately in females and males. The primary endpoint was clinical outcome at 6\u00a0months, assessed by the distribution of the modified Rankin Scale (mRS). Odds ratios (OR) and adjusted OR (aOR) with 95% confidence intervals (CI) were calculated using ordinal regression analyses. Secondary outcomes included good (mRS score 0\u20133) and excellent (mRS score 0\u20132) clinical outcome at 6\u00a0months, all-cause mortality at 30\u00a0days, all-cause mortality at 6\u00a0months, and in-hospital complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 812 patients, 577 (71%) were female, of whom 286 (50%) received TXA. Of the 235 males, 109 (46%) received TXA. Significant effect modification of sex on the relation between treatment group and clinical outcome was observed (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.044) in all aSAH patients. No significant differences in outcomes were observed among females. In males, ordinal regression analysis showed a difference in mRS distribution at 6\u00a0months to the detriment of males treated with TXA (aOR 1.94; 95% CI 1.20\u20133.14). No significant differences were observed between male treatment groups in secondary outcome measures.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In this post hoc analysis of the ULTRA trial, we observed a potential association between ultra-early, short-term TXA treatment and worse clinical outcomes in males at 6\u00a0months. Conversely, we did not observe a significant association between TXA treatment and clinical outcome in females. Consequently, these findings reinforce that routine use of TXA cannot be recommended in either females or males.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The trial was registered on ClinicalTrials.gov (NCT02684812).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-026-14037-z","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:07:39Z","timestamp":1787130459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tranexamic acid after aneurysmal subarachnoid hemorrhage is associated with worse outcome in males: post hoc analysis of the ULTRA trial"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7024-6255","authenticated-orcid":false,"given":"Raoul J.","family":"Koopmans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud A.","family":"Tjerkstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno R.","family":"Germans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervyn D. I.","family":"Vergouwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korn\u00e9","family":"Jellema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radboud W.","family":"Koot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyika D.","family":"Kruyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper F. C.","family":"Wolfs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Kieft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmin","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin","family":"Roks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"de Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loes J. A.","family":"Reichman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J. A. M.","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent I. H.","family":"Kwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taco C.","family":"van der Ree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri P.","family":"Bienfait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hieronymus D.","family":"Boogaarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina J. M.","family":"Klijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert A.","family":"Coert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles B. L. M.","family":"Majoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabri\u00ebl J. E.","family":"Rinkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvo B. W. E. M.","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Peter","family":"Vandertop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Verbaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ULTRA Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"issue":"9558","key":"14037_CR1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S0140-6736(07)60153-6","volume":"369","author":"J van Gijn","year":"2007","unstructured":"van Gijn J, Kerr RS, Rinkel GJ (2007) Subarachnoid haemorrhage. Lancet 369(9558):306\u2013318","journal-title":"Lancet"},{"issue":"9","key":"14037_CR2","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1161\/STROKEAHA.117.018118","volume":"48","author":"JV Lindbohm","year":"2017","unstructured":"Lindbohm JV, Kaprio J, Jousilahti P, Salomaa V, Korja M (2017) Risk factors of sudden death from subarachnoid hemorrhage. Stroke 48(9):2399\u20132404","journal-title":"Stroke"},{"issue":"2","key":"14037_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1161\/STROKEAHA.117.019328","volume":"49","author":"MN Stienen","year":"2018","unstructured":"Stienen MN, Germans M, Burkhardt JK, Neidert MC, Fung C, Bervini D et al (2018) Predictors of in-hospital death after aneurysmal subarachnoid hemorrhage: analysis of a nationwide database (swiss SOS [swiss study on aneurysmal subarachnoid hemorrhage]). Stroke 49(2):333\u2013340","journal-title":"Stroke"},{"issue":"8","key":"14037_CR4","volume":"2013","author":"MI Baharoglu","year":"2013","unstructured":"Baharoglu MI, Germans MR, Rinkel GJ, Algra A, Vermeulen M, van Gijn J, Roos YB (2013) Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2013(8):CD001245","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"14037_CR5","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1161\/STR.0b013e3182587839","volume":"43","author":"ES Connolly Jr","year":"2012","unstructured":"Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT et al (2012) Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American heart association\/American stroke association. Stroke 43(6):1711\u20131737","journal-title":"Stroke"},{"issue":"2","key":"14037_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000346087","volume":"35","author":"T Steiner","year":"2013","unstructured":"Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G, European SO (2013) European stroke organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis 35(2):93\u2013112","journal-title":"Cerebrovasc Dis"},{"issue":"7","key":"14037_CR7","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1161\/STR.0000000000000436","volume":"54","author":"BL Hoh","year":"2023","unstructured":"Hoh BL, Ko NU, Amin-Hanjani S, Chou S-Y, Cruz-Flores S, Dangayach NS et al (2023) Guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American heart association\/American stroke association. Stroke 54(7):e314\u2013e370","journal-title":"Stroke"},{"issue":"7","key":"14037_CR8","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00415-014-7365-0","volume":"261","author":"MR Germans","year":"2014","unstructured":"Germans MR, Coert BA, Vandertop WP, Verbaan D (2014) Time intervals from subarachnoid hemorrhage to rebleed. J Neurol 261(7):1425\u20131431","journal-title":"J Neurol"},{"issue":"7","key":"14037_CR9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJM198408163110703","volume":"311","author":"M Vermeulen","year":"1984","unstructured":"Vermeulen M, Lindsay KW, Murray GD, Cheah F, Hijdra A, Muizelaar JP et al (1984) Antifibrinolytic treatment in subarachnoid hemorrhage. N Engl J Med 311(7):432\u2013437","journal-title":"N Engl J Med"},{"issue":"1","key":"14037_CR10","first-page":"77","volume":"54","author":"Y Roos","year":"2000","unstructured":"Roos Y (2000) Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial. STAR Study Group Neurol 54(1):77\u201382","journal-title":"STAR Study Group Neurol"},{"issue":"11","key":"14037_CR11","volume":"11","author":"MR Germans","year":"2022","unstructured":"Germans MR, Dronkers WJ, Baharoglu MI, Post R, Verbaan D, Rinkel GJ, Roos YB (2022) Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 11(11):CD001245","journal-title":"Cochrane Database Syst Rev"},{"issue":"10269","key":"14037_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0140-6736(20)32518-6","volume":"397","author":"R Post","year":"2021","unstructured":"Post R, Germans MR, Tjerkstra MA, Vergouwen MDI, Jellema K, Koot RW et al (2021) Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial. Lancet 397(10269):112\u2013118","journal-title":"Lancet"},{"issue":"7","key":"14037_CR13","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1161\/01.STR.22.7.848","volume":"22","author":"C Sarti","year":"1983","unstructured":"Sarti C, Tuomilehto J, Salomaa V, Sivenius J, Kaarsalo E, Narva EV et al (1983) Epidemiology of subarachnoid hemorrhage in Finland from 1983 to 1985. Stroke 22(7):848\u2013853","journal-title":"Stroke"},{"issue":"3","key":"14037_CR14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.7326\/0003-4819-121-3-199408010-00002","volume":"121","author":"WT Longstreth","year":"1994","unstructured":"Longstreth WT, Nelson LM, Koepsell TD, van Belle G (1994) Subarachnoid hemorrhage and hormonal factors in women. A population-based case-control study. Ann Intern Med 121(3):168\u2013173","journal-title":"Ann Intern Med"},{"issue":"2","key":"14037_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/BF00313903","volume":"232","author":"T Stober","year":"1985","unstructured":"Stober T, Sen S, Anstatt T, Freier G, Schimrigk K (1985) Direct evidence of hypertension and the possible role of post-menopause oestrogen deficiency in the pathogenesis of berry aneurysms. J Neurol 232(2):67\u201372","journal-title":"J Neurol"},{"issue":"5","key":"14037_CR16","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.pjnns.2014.08.002","volume":"48","author":"GT Alfotih","year":"2014","unstructured":"Alfotih GT, Li F, Xu X, Zhang S (2014) Risk factors for re-bleeding of aneurysmal subarachnoid hemorrhage: meta-analysis of observational studies. Neurol Neurochir Pol 48(5):346\u2013355","journal-title":"Neurol Neurochir Pol"},{"issue":"2","key":"14037_CR17","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/STROKEAHA.121.037147","volume":"53","author":"AM Fuentes","year":"2022","unstructured":"Fuentes AM, Stone McGuire L, Amin-Hanjani S (2022) Sex differences in cerebral aneurysms and subarachnoid hemorrhage. Stroke 53(2):624\u2013633","journal-title":"Stroke"},{"issue":"Suppl_1","key":"14037_CR18","doi-asserted-by":"publisher","first-page":"AP434","DOI":"10.1161\/str.52.suppl_1.P434","volume":"52","author":"M Anadani","year":"2021","unstructured":"Anadani M, Kumar A, Phuah C-l, De Havenon AH, MacDonald R, Trialists SHI (2021) Abstract P434: sex differences in outcomes after subarachnoid hemorrhage: insight from the subarachnoid hemorrhage international trialists repository. Stroke 52(Suppl_1):AP434-AP","journal-title":"Stroke"},{"issue":"7","key":"14037_CR19","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00701-018-3549-1","volume":"160","author":"M Darkwah Oppong","year":"2018","unstructured":"Darkwah Oppong M, Iannaccone A, Gembruch O, Pierscianek D, Chihi M, Dammann P et al (2018) Vasospasm-related complications after subarachnoid hemorrhage: the role of patients\u2019 age and sex. Acta Neurochir (Wien) 160(7):1393\u2013400","journal-title":"Acta Neurochir (Wien)"},{"issue":"2","key":"14037_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.wneu.2012.06.023","volume":"79","author":"CC Larsen","year":"2013","unstructured":"Larsen CC, Astrup J (2013) Rebleeding after aneurysmal subarachnoid hemorrhage: a literature review. World Neurosurg 79(2):307\u201312","journal-title":"World Neurosurg"},{"issue":"8","key":"14037_CR21","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1161\/STROKEAHA.115.010037","volume":"46","author":"CE van Donkelaar","year":"2015","unstructured":"van Donkelaar CE, Bakker NA, Veeger NJ, Uyttenboogaart M, Metzemaekers JD, Luijckx GJ et al (2015) Predictive factors for rebleeding after aneurysmal subarachnoid hemorrhage: rebleeding aneurysmal subarachnoid hemorrhage study. Stroke 46(8):2100\u20136","journal-title":"Stroke"},{"key":"14037_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-14-143","volume":"14","author":"MR Germans","year":"2013","unstructured":"Germans MR, Post R, Coert BA, Rinkel GJ, Vandertop WP, Verbaan D (2013) Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials 14:143","journal-title":"Trials"},{"issue":"1","key":"14037_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-4118-5","volume":"21","author":"R Post","year":"2020","unstructured":"Post R, Germans MR, Coert BA, Rinkel GJE, Vandertop WP, Verbaan D (2020) Update of the ULtra-early TRranexamic acid after subarachnoid hemorrhage (ULTRA) trial: statistical analysis plan. Trials 21(1):199","journal-title":"Trials"},{"issue":"6","key":"14037_CR24","first-page":"985","volume":"68","author":"D CG","year":"1988","unstructured":"CG D (1988) Report of world federation of neurological surgeons committee on a universal subarachnoid hemorrhage grading scale. J Neurosurg 68(6):985\u20136","journal-title":"J Neurosurg"},{"issue":"1","key":"14037_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1227\/00006123-198001000-00001","volume":"6","author":"CM Fisher","year":"1980","unstructured":"Fisher CM, Kistler JP, Davis JM (1980) Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 6(1):1\u20139","journal-title":"Neurosurgery"},{"issue":"9","key":"14037_CR26","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1161\/01.STR.0000027437.22450.BD","volume":"33","author":"JT Wilson","year":"2002","unstructured":"Wilson JT, Hareendran A, Grant M, Baird T, Schulz UG, Muir KW, Bone I (2002) Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified rankin scale. Stroke 33(9):2243\u20136","journal-title":"Stroke"},{"issue":"2","key":"14037_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000262309","volume":"29","author":"PM Janssen","year":"2010","unstructured":"Janssen PM, Visser NA, Dorhout Mees SM, Klijn CJ, Algra A, Rinkel GJ (2010) Comparison of telephone and face-to-face assessment of the modified rankin scale. Cerebrovasc Dis 29(2):137\u20139","journal-title":"Cerebrovasc Dis"},{"issue":"4","key":"14037_CR28","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1161\/01.STR.0000157596.13234.95","volume":"36","author":"JT Wilson","year":"2005","unstructured":"Wilson JT, Hareendran A, Hendry A, Potter J, Bone I, Muir KW (2005) Reliability of the modified rankin scale across multiple raters: benefits of a structured interview. Stroke 36(4):777\u201381","journal-title":"Stroke"},{"issue":"23","key":"14037_CR29","doi-asserted-by":"publisher","first-page":"e2605","DOI":"10.1212\/WNL.0000000000201160","volume":"99","author":"MA Tjerkstra","year":"2022","unstructured":"Tjerkstra MA, Post R, Germans MR, Vergouwen MDI, Jellema K, Koot RW et al (2022) Tranexamic acid after aneurysmal subarachnoid hemorrhage: post hoc analysis of the ULTRA trial. Neurology 99(23):e2605\u2013e14","journal-title":"Neurology"},{"issue":"10210","key":"14037_CR30","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/S0140-6736(19)32233-0","volume":"394","author":"collaborators C-t","year":"2019","unstructured":"collaborators C-t (2019) Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet 394(10210):1713\u201323","journal-title":"Lancet"},{"issue":"2","key":"14037_CR31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bja.2022.03.032","volume":"129","author":"T Nutbeam","year":"2022","unstructured":"Nutbeam T, Roberts I, Weekes L, Shakur-Still H, Brenner A, Ageron FX (2022) Use of tranexamic acid in major trauma: a sex-disaggregated analysis of the clinical randomisation of an antifibrinolytic in significant haemorrhage (CRASH-2 and CRASH-3) trials and UK trauma registry (trauma and audit research network) data. Br J Anaesth 129(2):191\u20139","journal-title":"Br J Anaesth"},{"key":"14037_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.710495","volume":"12","author":"J Ren","year":"2021","unstructured":"Ren J, Qian D, Wu J, Ni L, Qian W, Zhao G et al (2021) Safety and efficacy of tranexamic acid in aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials. Front Neurol 12:710495","journal-title":"Front Neurol"},{"issue":"1\u20132","key":"14037_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF01402177","volume":"102","author":"SA Tsementzis","year":"1990","unstructured":"Tsementzis SA, Hitchcock ER, Meyer CH (1990) Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms a double-blind placebo-controlled study. Acta Neurochir (Wien) 102(1\u20132):1\u201310","journal-title":"Acta Neurochir (Wien)"},{"issue":"3","key":"14037_CR34","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s10143-020-01324-0","volume":"44","author":"JL de Faria","year":"2021","unstructured":"de Faria JL, da Silva BJ, Costa ESLT, Kilesse C, de Souza NB, Pereira CU et al (2021) Tranexamic acid in neurosurgery: a controversy indication-review. Neurosurg Rev 44(3):1287\u201398","journal-title":"Neurosurg Rev"},{"issue":"4","key":"14037_CR35","first-page":"339","volume":"47","author":"W Ng","year":"2015","unstructured":"Ng W, Jerath A, Wasowicz M (2015) Tranexamic acid: a clinical review. Anestezjol Intens Ter 47(4):339\u201350","journal-title":"Anestezjol Intens Ter"},{"issue":"1","key":"14037_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12630-011-9618-z","volume":"59","author":"RA Manji","year":"2012","unstructured":"Manji RA, Grocott HP, Leake J, Ariano RE, Manji JS, Menkis AH, Jacobsohn E (2012) Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. Can J Anaesth 59(1):6\u201313","journal-title":"Can J Anaesth"},{"issue":"2","key":"14037_CR37","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/anae.12516","volume":"69","author":"V Sharma","year":"2014","unstructured":"Sharma V, Katznelson R, Jerath A, Garrido-Olivares L, Carroll J, Rao V et al (2014) The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients. Anaesthesia 69(2):124\u201330","journal-title":"Anaesthesia"},{"key":"14037_CR38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.seizure.2016.02.011","volume":"36","author":"Z Lin","year":"2016","unstructured":"Lin Z, Xiaoyi Z (2016) Tranexamic acid-associated seizures: a meta-analysis. Seizure 36:70\u20133","journal-title":"Seizure"},{"issue":"1","key":"14037_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03799-9","volume":"25","author":"S Murao","year":"2021","unstructured":"Murao S, Nakata H, Roberts I, Yamakawa K (2021) Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta-analysis. Crit Care 25(1):380","journal-title":"Crit Care"},{"issue":"12","key":"14037_CR40","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209169","volume":"102","author":"MA Tjerkstra","year":"2024","unstructured":"Tjerkstra MA, Post R, Germans MR, Vergouwen MDI, Jellema K, Koot RW et al (2024) Ultra-early and short-term tranexamic acid treatment in patients with good and poor-grade aneurysmal subarachnoid hemorrhage. Neurology 102(12):e209169","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14037-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14037-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14037-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:16:56Z","timestamp":1789021016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-14037-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["14037"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-14037-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author(s) would like to disclose the following. The authors have completed the ICMJE uniform disclosure form. R.J. Koopmans reports no disclosures relevant to the manuscript; M.A. Tjerkstra reports a speakers fee and an Amsterdam Neurosciences POC Grant; M.R. Germans reports no disclosures relevant to the manuscript; M.D.I. Vergouwen reports no disclosures relevant to the manuscript; K. Jellema reports no disclosures relevant to the manuscript; R.W. Koot reports no disclosures relevant to the manuscript; N.D. Kruyt reports no disclosures relevant to the manuscript; J.F.C. Wolfs reports consulting fees from NuVasive Netherlands, Silony Medical and Bolt Circinus Medical Consultancy outside the submitted work; H. Kieft reports no disclosures relevant to the manuscript; D. Nanda reports no disclosures relevant to the manuscript; B. van der Pol reports no disclosures relevant to the manuscript; G. Roks reports no disclosures relevant to the manuscript; F. de Beer reports no disclosures relevant to the manuscript; L.J.A. Reichman reports no disclosures relevant to the manuscript; P.J.A.M. Brouwers reports no disclosures relevant to the manuscript; V.I.H. Kwa reports a grant from ZonMw (The Netherlands) project number 843004122; T.C. van der Ree reports no disclosures relevant to the manuscript; H.P. Bienfait reports no disclosures relevant to the manuscript; H.D. Boogaarts reports consulting fees paid to the Department of Neurosurgery, Radboud University Medical Center Nijmegen from Stryker neurovascular; C.J.M. Klijn reports grants from Promising Care funding scheme of the National Health Care Institute and ZonMw (2021038368), Penumbra Inc. and the Dutch Heart Foundation outside the submitted work, consulting fees from Alnylam, advisory committee for the setup of this study. In addition, C.J.M. Klijn reports to be a member of the DSMB of ENCHANTED2 (NCT04140110), MOSES (NCT NCT03961334), OPTIMAS (NCT03759938), ENRICH-AF (NCT03950076), chair of the DSMB of EMITT (NCT05318612) and ELAPSE (NCT05976685), participant in the ESO ICH (guideline) committee, and participant in a consensus panel meeting (May 2023) organized by EMCREG-International, a global educational consortium; this meeting was funded through an unrestricted educational grant from AstraZeneca.; R. van den Berg reports consulting fees for unrelated research and teaching activities from Cerenovus Neurovascular; B.A. Coert reports no disclosures relevant to the manuscript; J. Horn reports no disclosures relevant to the manuscript; C.B.L.M. Majoie reports grants from Stryker, Boehringer-Ingelheim, European Union, CVON\/Dutch Heart Foundation and Healthcare Evaluation Netherlands outside the submitted work and is a Shareholder of Nico-Lab, a company that focuses on the use of artificial intelligence for medical image analysis; G.J.E. Rinkel reports no disclosures relevant to the manuscript; Y.B.W.E.M. Roos is a minor stockholder of Nico-Lab; W.P. Vandertop reports no disclosures relevant to the manuscript; R. Post reports no disclosures relevant to the manuscript; D. Verbaan reports funding of Fonds NutsOhra.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have used the CONSORT checklist as a reporting checklist for this article.","order":2,"name":"Ethics","label":"Reporting checklist","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics committee of the Amsterdam University Medical Center (Amsterdam UMC, Amsterdam, the Netherlands) approved the trial protocol (2012_160#2012370).","order":3,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Because of the necessity of urgent administration of tranexamic acid and incapability of the vast majority of patients with subarachnoid hemorrhage to provide informed consent at short notice, the trial was done using deferred consent, under the exception from informed consent requirements for emergency research. As soon as the informed consent dialogue no longer interfered with proper and rapid diagnosis and aneurysm treatment, patients or their legally authorized representatives were notified about enrollment into the trial by the research team and asked to provide written informed consent for continued tranexamic acid treatment (if applicable) and data collection until the end of the trial.","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript has not been published elsewhere and is not under consideration by another journal. The manuscript complies with instructions to authors. Authorship requirements have been met and the final manuscript was approved by all authors.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"528"}}